Trial challenges COPD drug fears

Tiotropium cuts mortality in COPD patients by 16 per cent compared with placebo, results of a 5,993-patient study show.

The long-acting anticholinergic drug, marketed as Spiriva, reduced exacerbations, delayed time to first exacerbation and cut the risk of exacerbations leading to hospital admission.

However, it failed to statistically significantly reduce decline in FEV1 after four years, the trial's primary endpoint.

The finding of reduced mortality contrasts with a recent JAMA analysis suggesting anticholinergics raise CVD risk.

  • NEJM 2008; 359: 1,543-54.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

Sign pointing to hospital

NHS England seeks to clarify GPs' responsibilities when using advice and guidance

New guidance from NHS England has set out the clinical responsibilities and medicolegal...

Widespread joint pain - red flag symptoms

Presentations and red flag symptoms that may alert you to potentially serious conditions...

Talking General Practice logo

Podcast: Supporting neurodivergent doctors and staff in general practice

Talking General Practice speaks to GPs Dr Beckie Akroyd and Dr Catherine Bell about...

BMA Scotland GP committee chair Dr Andrew Buist

General practice in Scotland 'in serious trouble', warns BMA Scotland GP chair

General practice in Scotland has reached a tipping point, with demand far outstripping...

Hospital entrance

NHS England issues warning over norovirus and rising winter pressures

Almost three times as many people were in hospital with norovirus last week compared...

BMA Northern Ireland GP committee chair Dr Alan Stout

Northern Ireland GPs face deepest-ever crisis as practices hand back contracts

Northern Ireland's GP leader has warned that general practice in the region is facing...